HealthcareServices

Global Thyroid Eye Disease (TED) Market Report 2026–2030: Data-Driven Growth Insights

March 3, 2026March 3, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the thyroid eye disease (ted) market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Thyroid Eye Disease (TED) Market in 2030?

The market size for thyroid eye disease (ted) has shown considerable growth in recent years. It is anticipated to increase from $2.29 billion in 2025 to $2.44 billion in 2026, at a compound annual growth rate (CAGR) of 6.6%. The expansion observed historically can be linked to factors like the rising occurrence of autoimmune thyroid disorders, enhanced clinical detection of ted symptoms, more widespread adoption of corticosteroid therapies, the extension of ophthalmology services, and an uptick in referral rates from endocrinology clinics.

The market for thyroid eye disease (TED) is projected to experience substantial expansion over the upcoming years, with its valuation anticipated to reach $3.12 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.3%. This projected growth during the forecast period can be attributed to several factors, including the increasing integration of new biologic treatments like teprotumumab, heightened investments in research for autoimmune diseases, the wider availability of minimally invasive surgical procedures, an escalating emphasis on enhancing patients’ quality of life, and a surging need for individualized TED therapies. Furthermore, key trends observed during this period will encompass a greater uptake of targeted biologic remedies, an increased application of combined treatment methods, an intensified focus on intervening early in the disease progression, the broadened reach of specialized ophthalmic services, and the development of more sophisticated patient-centric care models.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21300&type=smp

What Drivers Are Influencing Production Trends In The Thyroid Eye Disease (TED) Market?

The thyroid eye disease (TED) market is anticipated to expand due to an increase in thyroid disorders. These disorders are medical conditions impacting the thyroid gland’s function, causing hormone production imbalances, which manifest as hypothyroidism, hyperthyroidism, goiter, and thyroid eye disease. The increase in thyroid disorders stems from factors like heightened iodine consumption, autoimmune conditions, genetic susceptibility, and enhanced awareness contributing to better diagnostic rates. Thyroid Eye Disease (TED) itself adds to the growing number of thyroid disorder cases, being a frequent and severe complication of Graves’ disease, thereby elevating the total impact and recognition of thyroid-related conditions. As an illustration, the Canadian Cancer Society, a Canada-based non-profit, community-based organization, reported in May 2024 that an estimated 6,600 new thyroid cancer diagnoses are anticipated in Canada in 2024, alongside a projection of approximately 280 deaths. Consequently, the surge in thyroid disorders is a key impetus for the expansion of the thyroid eye disease (TED) market.

Which Segments Are Gaining Traction In The Thyroid Eye Disease (TED) Market?

The thyroid eye disease (ted) market covered in this report is segmented –

1) By Treatment Type: Medical, Surgical, Combination Of Medical And Surgical

2) By Disease Severity: Mild, Moderate, Severe

3) By Drug Type: Biologics, Small Molecules, Other Drug Types

4) By Route Of Administration: Oral, Intravenous, Subcutaneous

5) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Medical: Corticosteroids, Teprotumumab, Antithyroid Medications

2) By Surgical: Orbital Decompression Surgery, Eyelid Surgery, Strabismus Surgery

3) By Combination Of Medical and Surgical: Combination of Corticosteroids and Orbital Decompression, Combination of Teprotumumab and Eyelid Surgery

What Trends Are Projected To Support The Growth Of The Thyroid Eye Disease (TED) Market?

Leading companies in the thyroid eye disease (TED) market are concentrating on advanced solutions, like monoclonal antibody therapies, to create more potent, precise treatments aimed at diminishing inflammation, ameliorating proptosis, and elevating overall patient well-being. Monoclonal antibody therapies are medical interventions utilizing lab-created antibodies that replicate the immune system’s capacity to identify and neutralize particular pathogens or abnormal cells. A notable example occurred in September 2024, when Amgen Inc., a US-based biotechnology firm, disclosed that Japan’s Ministry of Health, Labour and Welfare (MHLW) granted approval for TEPEZZA (teprotumumab) to treat active thyroid eye disease (TED), a rare autoimmune condition that can threaten vision. This therapy stands as the pioneering and sole FDA-approved treatment specifically for TED, delivering a focused approach to alleviate inflammation, swelling, and other severe symptoms linked to the ailment. The sanction holds particular significance for patients in Japan, presenting a novel, efficacious choice to address TED, a rare and worsening disorder characterized by severe eye bulging, visual impairment, and ocular discomfort.

Who Are The Primary Competitors In The Global Thyroid Eye Disease (TED) Market?

Major companies operating in the thyroid eye disease (ted) market are Viridian Therapeutics Inc, Tourmaline Bio Inc, Sling Therapeutics Inc, Immunovant Inc, Hoffmann-La Roche AG, H Lundbeck A S, Alumis Inc, Changchun GeneScience Pharmaceutical Co Ltd, Minghui Pharmaceutical Inc, Amgen Inc, Crinetics Pharmaceuticals Inc, Ollin Biosciences Inc, Lycia Therapeutics Inc, Inflammasome Therapeutics Inc, Novartis Pharmaceuticals Corp, AdvanceCOR Inc, Worg Pharmaceuticals Inc, AV7 Limited, EVOQ Therapeutics Inc, ValenzaBio Inc, Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co Ltd, Sanofi SA, Alexion Pharmaceuticals Inc, Septerna Corporation

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/thyroid-eye-disease-ted-global-market-report

Which Regions Are Projected To Dominate The Thyroid Eye Disease (TED) Market In The Coming Years?

North America was the largest region in the thyroid eye disease (TED) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the thyroid eye disease (ted) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Thyroid Eye Disease (TED) Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21300&type=smp

Browse Through More Reports Similar to the Global Thyroid Eye Disease (TED) Market 2026, By The Business Research Company

Thyroid Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-diagnostics-global-market-report

Eye Melanoma Market Report 2026

https://www.thebusinessresearchcompany.com/report/eye-melanoma-global-market-report

Thyroid Function Test Market Report 2026

https://www.thebusinessresearchcompany.com/report/thyroid-function-test-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795